BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15817265)

  • 1. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
    Popovic N; Maingay M; Kirik D; Brundin P
    Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
    Ebert AD; Barber AE; Heins BM; Svendsen CN
    Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
    Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
    Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
    Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
    Georgievska B; Carlsson T; Lacar B; Winkler C; Kirik D
    Eur J Neurosci; 2004 Dec; 20(11):3121-30. PubMed ID: 15579166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
    Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
    J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
    Ericson C; Georgievska B; Lundberg C
    Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A; Bauer M; Thöny B; Aebischer P
    J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of lentiviral vector-mediated overexpression of nerve growth factor and glial cell line-derived neurotrophic factor on regenerating sensory and motor axons in the transected peripheral nerve.
    Tannemaat MR; Eggers R; Hendriks WT; de Ruiter GC; van Heerikhuize JJ; Pool CW; Malessy MJ; Boer GJ; Verhaagen J
    Eur J Neurosci; 2008 Oct; 28(8):1467-79. PubMed ID: 18973572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal gene delivery of glial cell line-derived neurotrophic factor ameliorated paraplegia in rats after spinal ischemia.
    Chou AK; Yang LC; Wu PC; Wong WT; Liu GS; Chen JT; Howng SL; Tai MH
    Brain Res Mol Brain Res; 2005 Feb; 133(2):198-207. PubMed ID: 15710236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
    Lo Bianco C; Déglon N; Pralong W; Aebischer P
    Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal transplantation in a transgenic mouse model of Huntington's disease.
    Dunnett SB; Carter RJ; Watts C; Torres EM; Mahal A; Mangiarini L; Bates G; Morton AJ
    Exp Neurol; 1998 Nov; 154(1):31-40. PubMed ID: 9875265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuroprotective effect of glial cell line-derived neurotrophic factor in fibrin glue against chronic focal cerebral ischemia in conscious rats.
    Cheng H; Huang SS; Lin SM; Lin MJ; Chu YC; Chih CL; Tsai MJ; Lin HC; Huang WC; Tsai SK
    Brain Res; 2005 Feb; 1033(1):28-33. PubMed ID: 15680336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
    Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
    Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
    Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T
    Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.
    McBride JL; During MJ; Wuu J; Chen EY; Leurgans SE; Kordower JH
    Exp Neurol; 2003 Jun; 181(2):213-23. PubMed ID: 12781994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ; Manley K; Messer A
    Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.